MASTER-DAPT: A Further Step Toward Long-Term P2Y12 Blocker Monotherapy After PCI

The MASTER-DAPT trial confirms that shortening dual antiplatelet therapy (DAPT) after PCI significantly reduces bleeding risk without increasing ischemic events at 15 months. These findings further support a shift toward long-term P2Y12 inhibitor monotherapy as a safe and effective alternative to traditional aspirin-based strategies.